Treatment goal
Insulin independence without chronic immunosuppression — designed to solve both halves of the durable-cure bar in one product.
Type of approach
Manufactured (iPSC-derived) islets combined with immune-evasion gene engineering.
Current evidence
Preclinical, IND-enabling — data presented at ADA 2026, not yet peer-reviewed or published.
Trial phase & enrollment
Preclinical. No participants yet; IND submission targeted for Q4 2026.
Who may qualify
Not applicable — no clinical trial is open yet.Revisit once an IND is cleared and enrollment criteria are published.
Location & travel
Not applicable yet.
What participants would undergo
Not yet defined publicly for a human protocol.We do not speculate here — this field updates once Century publishes trial design.
Possible benefits
Preclinical data suggests sustained glucose control and immune evasion without immunosuppression, if it translates to humans — an if that hasn't been tested yet.
Known & unknown risks
Unknown in humans — this is the central caveat for the whole entry. Preclinical safety in animal/lab models does not predict human safety or efficacy.
Immunosuppression requirement
Designed to avoid it — unproven in humans.
Results so far
8-month sustained glucose control and immune evasion in preclinical models, per Century's ADA 2026 presentation.
Definition of success used
Preclinical proof of concept — sustained control and evasion in the model system used, not a human clinical endpoint.
Duration / follow-up
8 months of preclinical data reported to date.
Cost & compensation
Not applicable — no trial open.
Sponsor
Century Therapeutics.
How to find a site
Not applicable yet.Will apply once an IND clears and a trial registers on ClinicalTrials.gov.